daxas.co.uk Report : Visit Site

Technical data of the daxas.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host daxas.co.uk. Currently, hosted in United States and its service provider is Corporation Service Company .

the related websites

medicines.org.uk daxaspa.com netdoctor.co.uk pharmafile.com gov.uk xpil.medicines.org.uk evidence.nhs.uk weldricks.co.uk scottishmedicines.org.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

skip to content skip to navigation cookie policy this website uses cookies to help us give you the best experience when you visit. by using this website you consent to our use of these cookies. find out more about how we use cookies and how to manage them by reading our cookie notice. close search menu search search search close what science can do what science can do labtalk blog our technology drug modalities our science our science pipeline publications cambridge gothenburg gaithersburg imed biotech unit medimmune global medicines development our focus areas cardiovascular, renal and metabolism oncology respiratory inflammation and autoimmunity neuroscience infection and vaccines all focus areas all medicines our company our company our strategy our people leadership team careers careers global careers site investors investor relations stock exchange announcements results and presentations annual reports governance dividend policy debt investors adr programme shareholder information key facts faqs partnering partnering partnering case studies get in touch business mentoring astrazeneca exchange media media centre image library broadcast videos articles press releases archive sustainability sustainability access to healthcare environmental protection ethics and transparency resources more hide astrazeneca websites global site results from real world evidence presented at the esc congress 2018 advances clinical practice read more view modalities advancements in biotechnology have expanded our toolkit of drug modalities our focus areas cardiovascular, renal and metabolism science is at the heart of everything we do. what drives you today? ground-breaking science career opportunities to partner with astrazeneca investor information ground-breaking science although significant advances have been made, we still need to work on not just the treatment of chronic lung disease but also on disease modification and cure maria belvisi, vice president and head, respiratory, inflammation & autoimmunity research, imed biotech unit learn more about our imed biotech unit publications our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement. view our publications we have 143 projects in our pipeline view pipeline colab high throughput screening system explore our technology our new facility in cambridge will be an open, welcoming and vibrant centre explore all our science centres corporate press release astrazeneca provides update on aeristo phase iiib trial for bevespi aerosphere in chronic obstructive pulmonary disease 23 august 2018 corporate press release tagrisso approved in japan for 1st-line treatment of egfr-mutated non-small cell lung cancer 21 august 2018 our science at astrazeneca, science is at the core of everything we do. but more than that, science is who we are. find out more career opportunities there is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it. jonathan dry, principal scientist, bioinformatics, oncology, innovative medicines & early development meet our people acoustic mass spectrometer platform explore our technology three strategic science centres our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries find our about our science inhibiting stages in the dna damage response pathway read more of our stories our focus areas cardiovascular and metabolic diseases oncology respiratory inflammation and autoimmunity neuroscience infection and vaccines astrazeneca job search at astrazeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. if you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us. search for a job now start a career that will help improve life for millions. learn more about our school/college student, undergraduate, graduate and post doctorate programmes with us in our early careers page. find your early career now working at astrazeneca we need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. find out more about our teams and the work they do. find out more on the careers section to partner with astrazeneca i often say being in business development is having the best job in astrazeneca in terms of the motivation, interest and challenging work we do with incredibly smart people from science and business on projects that really make a difference for our partners and patients. shaun grady, vice-president business development operations see our partnering contacts horizon discovery and astrazeneca: searching for novel, personalised cancer therapies see more partnering case studies partnering with us we partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise. learn more about our areas of interest open innovation our open innovation platform is designed to foster open innovation partnerships spanning all stages of drug discovery and development. learn more on the open innovation site corporate press release astrazeneca heads to 2018 asco annual meeting with its diversified oncology portfolio and next-generation pipeline 24 may 2018 corporate press release updated overall survival data for lynparza in brca-mutated her2-negative metastatic breast cancer presented at aacr 15 april 2018 collaborate with us the best science doesn't happen in isolation. visit our partnering section investor information “the performance in the first half demonstrated that we remain firmly on track to return our company to product sales growth in 2018. our new medicines performed strongly and have established themselves as major drivers of product sales, including lynparza, tagrisso and imfinzi in oncology, brilinta and farxiga in cvrm and fasenra in respiratory. emerging markets, led by china, delivered double-digit growth." pascal soriot, executive director and chief executive officer meet our people latest presentation h1 2018 results view quarterly results financial calendar find all the latest dates for ex-dividends, investor roadshows and more see all key dates latest financial information see all the results and presentations read the latest annual report (2017) stock exchange announcements find all the latest announcements from the stock exchange view latest announcements corporate press release astrazeneca provides update on aeristo phase iiib trial for bevespi aerosphere in chronic obstructive pulmonary disease 23 august 2018 corporate press release tagrisso approved in japan for 1st-line treatment of egfr-mutated non-small cell lung cancer 21 august 2018 investors find out more about investing in astrazeneca, everything from investor relations to dividend policies. visit our investor relations astrazeneca websites this website is intended for people seeking information on astrazeneca's worldwide business. our country sites can be located in the az network. resources all resources open innovation externally sponsored scientific research medimmune us prescription assistance programmes global clinical trials information medicines report a possible side effect pearl therapeutics quick links media investor relations partnering careers sustainability modern slavery statement supplier information social media facebook linkedin twitter glassdoor instagram utility links legal notice and terms of use privacy notice cookie policy site map contact us © astrazeneca 2018 you are now leaving astrazeneca.com you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. astrazeneca provides

URL analysis for daxas.co.uk

https://www.astrazeneca.com/our-company.html
https://www.astrazeneca.com/our-science.html
https://www.astrazeneca.com/investor-relations/results-and-presentations.html
https://www.astrazeneca.com/our-company/contact-us.html
https://www.astrazeneca.com/investor-relations/astrazeneca-adr-programme.html
https://www.astrazeneca.com/sustainability/ethics-and-transparency.html
https://www.astrazeneca.com/media-centre.html
https://www.astrazeneca.com/sustainability/resources.html
https://www.astrazeneca.com/our-company/our-strategy.html
https://www.astrazeneca.com/astrazeneca-exchange.html
https://www.astrazeneca.com/global/en/sitemap.html
https://www.astrazeneca.com/careers.html
https://www.astrazeneca.com/investor-relations/stock-exchange-announcements.html
https://www.astrazeneca.com/our-focus-areas/infection-and-vaccines.html
https://www.astrazeneca.com/our-science/gaithersburg.html
glassdoor.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "daxas.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 3 seconds

WHOIS lookup made at 17:07:24 30-Aug-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS daxas.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME daxas.co.uk

NSERVER

  DNS2.CSCDNS.NET 69.36.145.33

  DNS1.CSCDNS.NET 209.112.114.33

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .